文献速递心力衰竭与心肌病

全球急性心力衰竭患者特征、诱因及初始管理的差异:REPORT-HF研究

Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure.
PubMed 文献 · JAMA Cardiol · 2020-01-01

结果发现各区域患者在许多方面相似,但治疗时机和类型存在重要差异,提示区域特异性的管理差距可能与患者结局相关。

要点

  • 缺血是东南亚、西太平洋和东地中海及非洲地区常见的急性心衰诱因。
  • 东南亚、西太平洋和东欧的正性肌力药物使用率约为北美和西欧的3倍。

核心结论

  • 全球急性心衰患者特征相似,但治疗时机和类型存在区域差异,提示管理差距可能与结局相关。

主要发现

  • 缺血为东南亚(596/2329,25.6%)、西太平洋(572/3354,17.1%)和东地中海及非洲(364/2241,16.2%)常见诱因;饮食和药物不依从在北美最常见(306/1592,19.2%)。

关键数值与推荐

  • 年龄增长(OR 1.0,95%CI 1.00-1.02)、心衰病因(缺血:OR 1.65,95%CI 1.11-2.44;瓣膜:OR 2.10,95%CI 1.36-3.25)、肌酐>2.75 mg/dL(OR 1.85,95%CI 0.71-2.40)及胸片淤血征象(OR 2.03,95%CI 1.39-2.97)与院内死亡率增加相关。
  • 年轻年龄(OR -0.04,95%CI -0.05至-0.02)、心衰病因(缺血:OR 0.77,95%CI 0.26-1.29;瓣膜:OR 2.01,95%CI 1.38-2.65)、肌酐>2.75 mg/dL(OR 1.16,95%CI 0.31-2.00)及胸片淤血征象(OR 1.02,95%CI 0.57-1.47)与院内住院时间延长相关。

临床怎么用

  • 临床应关注区域治疗差异,尤其北美静脉治疗延迟及部分地区正性肌力药物过度使用,优化急性心衰初始管理。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Acute heart failure (AHF) precipitates millions of hospital admissions worldwide, but previous registries have been country or region specific. OBJECTIVE: To conduct a prospective contemporaneous comparison of AHF presentations, etiologic factors and precipitants, treatments, and in-hospital outcomes among global regions through the International Registry to Assess Medical Practice with Longitudinal Observation for Treatment of Heart Failure (REPORT-HF). DESIGN, SETTING, AND PARTICIPANTS: A total of 18 553 adults were enrolled during a hospitalization for AHF. Patients were recruited from the acute setting in Western Europe (WE), Eastern Europe (EE), Eastern Mediterranean and Africa (EMA), Southeast Asia (SEA), Western Pacific (WP), North America (NA), and Central and South America (CSA). Patients with AHF were approached for consent and excluded only if there was recent participation in a clinical trial. Patients were enrolled from July 23, 2014, to March 24, 2017. Statistical analysis was conducted from April 18 to June 29, 2018; revised analyses occurred between August 6 and 29, 2019. MAIN OUTCOMES AND MEASURES: Heart failure etiologic factors and precipitants, treatments, and in-hospital outcomes among global regions. RESULTS: A total of 18 553 patients were enrolled at 358 sites in 44 countries. The median age was 67.0 years (interquartile range [IQR], 57-77), 11 372 were men (61.3%), 9656 were white (52.0%), 5738 were Asian (30.9%), and 867 were black (4.7%). A history of HF was present in more than 50% of the patients and 40% were known to have a prior left-ventricular ejection fraction lower than 40%. Ischemia was a common AHF precipitant in SEA (596 of 2329 [25.6%]), WP (572 of 3354 [17.1%]), and EMA (364 of 2241 [16.2%]), whereas nonadherence to diet and medications was most common in NA (306 of 1592 [19.2%]). Median time to the first intravenous therapy was 3.0 (IQR, 1.4-5.6) hours in NA; no other region had a median time above 1.2 hours (P < .001). This treatment delay remained after adjusting for severity of illness (P < .001). Intravenous loop diuretics were the most common medication administered in the first 6 hours of AHF management across all regions (65.4%-89.9%). Despite similar initial blood pressure across all regions, inotropic agents were used approximately 3 times more often in SEA, WP, and EE (11.3%-13.5%) compared with NA and WE (3.1%-4.3%) (P < .001). Older age (odds ratio [OR], 1.0; 95% CI, 1.00-1.02), HF etiology (ischemia: OR, 1.65; 95% CI, 1.11-2.44; valvular: OR, 2.10; 95% CI, 1.36-3.25), creatinine level greater than 2.75 mg/dL (OR, 1.85; 95% CI, 0.71-2.40), and chest radiograph signs of congestion (OR, 2.03; 95% CI, 1.39-2.97) were all associated with increased in-hospital mortality. Similarly, younger age (OR, -0.04; 95% CI, -0.05 to -0.02), HF etiology (ischemia: OR, 0.77; 95% CI, 0.26-1.29; valvular: OR, 2.01; 95% CI, 1.38-2.65), creatinine level greater than 2.75 mg/dL (OR, 1.16; 95% CI, 0.31-2.00), and chest radiograph signs of congestion (OR, 1.02; 95% CI, 0.57-1.47) were all associated with increased in-hospital LOS. CONCLUSIONS AND RELEVANCE: Data from REPORT-HF suggest that patients are similar across regions in many respects, but important differences in timing and type of treatment exist, identifying region-specific gaps in medical management that may be associated with patient outcomes.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Filippatos G, Angermann CE, Cleland JGF, et al. Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. JAMA Cardiol. 2020. PMID: 31913404. doi:10.1001/jamacardio.2019.5108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。